Teleflex Announces Publication of Early Patient Experience Data Highlighting the UroLift® System as a Superior Treatment to ...
June 22 2020 - 6:30AM
Teleflex Incorporated (NYSE: TFX) today announced the publication
of data from a study comparing patient experience of those treated
with the UroLift® System for benign prostatic hyperplasia (BPH) to
those who received the Rezum™ steam injection. Results highlighting
early positive experience following treatment with the UroLift
System were published in the Canadian Journal of Urology.
“These published results further emphasize the unique benefits
of the minimally invasive UroLift System for men dealing with the
burdensome symptoms of BPH,” said Dave Amerson, president of
Teleflex Interventional Urology business unit. “Not only does the
UroLift System provide durable and lasting symptom relief, but it
also allows men to return to a better quality of life. We are
pleased to see that these results highlight the distinct advantages
of the UroLift System compared to other minimally invasive
treatments and that they are consistent to those seen in past
clinical studies, demonstrating preservation of sexual function,
rapid return to daily activities and high patient satisfaction
among patients treated with the UroLift System.”
The study compared 53 non-retention patients from two U.S. sites
who received treatment with either the UroLift System or tissue
ablation with the Rezum steam injection. To report the early
postoperative patient experience, the study measured symptom
response, catheterization rates, and recovery and satisfaction at
up to two months post-treatment.
Early post-operative results from the study showed positive
differences for patients treated with the UroLift System compared
to Rezum, including better sexual function outcomes, less
interference in daily activities and higher patient satisfaction
following the procedure. Additionally, results from the study found
more than twice as many patients who received the UroLift System
treatment reported being catheter free at day three (93%) compared
to those who received Rezum (45%). At the 30-day mark, absolute
symptom score was 45% better among patients treated with the
UroLift System compared to those treated with Rezum.
Results from the study also found that 83% of patients treated
with the UroLift System reported they were satisfied with their
treatment compared to 65% of patients treated with Rezum. Patients
reported the treatment improved their urinary symptoms when treated
with the UroLift System (97%) compared to those treated with Rezum
(70%). Results also showed that patients in the UroLift System
treatment group reported no interference with sports, and little
interference with entertainment and community activities, while
nearly half of the Rezum group patients reported that their
procedure interfered with these activities. Additionally, patients
that received the UroLift System reported better absolute scores
for erectile function (61%) and ejaculatory function (33%) compared
to Rezum patients.
“These data suggest the UroLift System treatment provides
patients a superior experience with better preservation of sexual
function, lower catheterization rates, less daily interference, and
better overall satisfaction at one month following treatment
compared to Rezum,” said Ronald Tutrone, M.D., Chesapeake Urology
Research Associates in Baltimore, Maryland. “The UroLift System is
an accepted standard of care treatment for men with enlarged
prostate and the Prostatic Urethral Lift (PUL) is recommended by
the American Urologic Association BPH Treatment Guidelines.”
“The UroLift System is a game-changer for patients suffering
from BPH symptoms and is supported by a robust portfolio of
clinical evidence as well as a growing body of real-world
evidence,” said Dr. William Schiff, M.D., Urology Associates of
Central California in Fresno, California. “Providers should be
encouraged by these findings showing the UroLift System offers a
positive treatment experience and rapid recovery, allowing men to
return to their daily activities with minimal downtime.”
About the UroLift® SystemThe UroLift®
System is a minimally invasive treatment for lower urinary tract
symptoms due to benign prostatic hyperplasia (BPH). It is indicated
for the treatment of symptoms of an enlarged prostate up to 100cc
in men 45 years or older. The UroLift permanent implants, delivered
during an outpatient procedure, relieve prostate obstruction
without cutting, heating, or removing prostate tissue. The UroLift
System is the only leading BPH procedure shown to not cause new
onset, sustained erectile or ejaculatory dysfunction.1,2,5 Most
common adverse events are temporary and can include hematuria,
dysuria, micturition urgency, pelvic pain, and urge incontinence.1
The Prostatic Urethral Lift procedure (using the UroLift System) is
recommended for the treatment of BPH in both the American
Urological Association and European Association of Urology clinical
guidelines. More than 175,000 men have been treated with the
UroLift System in select markets worldwide.* As with any medical
procedure, individual results may vary. Learn more at
www.UroLift.com.
About Teleflex Interventional UrologyThe
Teleflex Interventional Urology Business Unit is dedicated to
developing innovative, minimally invasive and clinically effective
devices that address unmet needs in the field of urology. Our focus
is on improving the standard of care for patients with BPH using
the UroLift System, a minimally invasive permanent implant system
that treats symptoms while preserving sexual
function.**6,7 Learn more at www.NeoTract.com.
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular and interventional access,
surgical, anesthesia, cardiac care, urology, emergency medicine and
respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For
more information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch®, UroLift® and Weck® – trusted brands
united by a common sense of purpose.
Rezum™ is a trademark of Boston Scientific Corporation or its
affiliates.
Dr. Ronald Tutrone and Dr. William Schiff are investigators in
the clinical study sponsored by Teleflex Incorporated.
Contacts: |
|
For Teleflex Incorporated: |
Media: |
Jake Elguicze, 610.948.2836 |
Nicole Osmer, 650.454.0504 |
Treasurer and Vice President, Investor Relations |
nicole@healthandcommerce.com |
1. Roehrborn, J Urology 2013 LIFT Study2. AUA BPH Guidelines
2003, 2010, 20183. Naspro, Eur Urol 20094. Montorsi, J Urol 20085.
McVary, J Sex Med 2016 6. Shore, Can J Urol 2014 Local Study7.
Speakman et al. 2014 BJUI International *Management estimate
based on product sales and average units per procedure** No
instances of new, sustained erectile or ejaculatory dysfunction
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024